TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.

PHASE2UnknownINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 30, 2021

Primary Completion Date

December 31, 2022

Study Completion Date

July 31, 2023

Conditions
Esophageal Neoplasms
Interventions
DRUG

Paclitaxel + Cisplatin + TQB2450 injection+ Anlotinib

TQB2450 injection: 1200 mg, i.v.gtt , d1;Anlotinib 10mg, po.qd , d1-14;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to Anlotinib (10mg, po.qd , d1-14)+TQB2450 injection(1200 mg, i.v.gtt , d1). The regimen is repeated every 3 weeks until the disease progresses.

DRUG

Paclitaxel + Cisplatin + TQB2450 injection

TQB2450 injection: 1200 mg, i.v.gtt , d1;Paclitaxel 135mg/m2, i.v.gtt , d1; Cisplatin 60-75mg/m2, i.v.gtt , d1-d3; The above schemes are repeated every three weeks. After 4-6 cycles, the regimen is changed to TQB2450 injection(1200 mg, i.v.gtt , d1). The regimen is repeated every 3 weeks until the disease progresses.

Trial Locations (5)

450003

Henan Provincial People's Hospital, Zhengzhou

450008

Henan Cancer Hospital, Zhengzhou

455000

AnYang Tumor Hospital, Anyang

The People's Hospital Of AnYang City, Anyang

471000

First Affiliated Hospital of Henan University of Science and Technolog, Luoyang

All Listed Sponsors
collaborator

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY

lead

Henan Cancer Hospital

OTHER_GOV